NREP

Summary

NREP (neuronal regeneration related protein, HGNC:16834) is a protein-coding gene on chromosome 5q22.1, encoding Neuronal regeneration-related protein (Q16612). May have roles in neural function.

Predicted to be involved in axon regeneration; regulation of neuron differentiation; and regulation of transforming growth factor beta receptor signaling pathway. Predicted to be located in cytoplasm.

Source: NCBI Gene 9315 — RefSeq curated summary.

At a glance

• GWAS associations: 28
• Clinical variants (ClinVar): 32 total
• MANE Select transcript: NM_004772

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16834
Approved symbol	NREP
Name	neuronal regeneration related protein
Location	5q22.1
Locus type	gene with protein product
Status	Approved
Aliases	P311, D4S114, PRO1873, PTZ17, SEZ17
Ensembl gene	ENSG00000134986
Ensembl biotype	protein_coding
OMIM	607332
Entrez	9315

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 28 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000257435, ENST00000379671, ENST00000395634, ENST00000419114, ENST00000446294, ENST00000447165, ENST00000450761, ENST00000453526, ENST00000455559, ENST00000503429, ENST00000504018, ENST00000505864, ENST00000507032, ENST00000507742, ENST00000508161, ENST00000508870, ENST00000509025, ENST00000509427, ENST00000509979, ENST00000513100, ENST00000513684, ENST00000514515, ENST00000515855, ENST00000875801, ENST00000875802, ENST00000875803, ENST00000875804, ENST00000920636, ENST00000920637, ENST00000920638, ENST00000920639, ENST00000920640, ENST00000920641, ENST00000920642

RefSeq mRNA: 11 — MANE Select: NM_004772 NM_001142474, NM_001142475, NM_001142476, NM_001142477, NM_001142478, NM_001142479, NM_001142480, NM_001142481, NM_001142482, NM_001142483, NM_004772

CCDS: CCDS4105, CCDS47255

Canonical transcript exons

ENST00000257435 — 4 exons

Exon	Start	End
ENSE00001770789	111729303	111731046
ENSE00002058117	111757136	111757194
ENSE00003586374	111755770	111755830
ENSE00003666801	111735430	111735507

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 54.3110 / max 1586.9318, expressed in 1656 samples.

FANTOM5 promoters (19 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62926	22.1716	1208
62929	11.0081	1139
62928	6.5038	992
62933	4.3988	1371
62932	4.1833	1227
62930	1.8474	580
62927	1.4003	632
62931	0.5781	256
62925	0.5683	185
62935	0.5483	258

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.85	gold quality
paraflocculus	UBERON:0005351	99.76	gold quality
ganglionic eminence	UBERON:0004023	99.73	gold quality
embryo	UBERON:0000922	99.63	gold quality
cerebellar hemisphere	UBERON:0002245	99.45	gold quality
tibia	UBERON:0000979	99.44	gold quality
ventricular zone	UBERON:0003053	99.42	gold quality
cerebellum	UBERON:0002037	99.41	gold quality
cerebellar cortex	UBERON:0002129	99.41	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.37	gold quality
adrenal tissue	UBERON:0018303	98.56	gold quality
pons	UBERON:0000988	98.14	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.00	gold quality
cartilage tissue	UBERON:0002418	97.95	gold quality
frontal pole	UBERON:0002795	97.62	gold quality
tendon of biceps brachii	UBERON:0008188	97.58	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.54	gold quality
biceps brachii	UBERON:0001507	97.53	gold quality
prefrontal cortex	UBERON:0000451	97.52	gold quality
orbitofrontal cortex	UBERON:0004167	97.28	gold quality
endothelial cell	CL:0000115	97.26	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.14	gold quality
adult organism	UBERON:0007023	97.11	gold quality
visceral pleura	UBERON:0002401	97.06	gold quality
primary visual cortex	UBERON:0002436	96.98	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	96.94	gold quality
frontal cortex	UBERON:0001870	96.90	gold quality
secondary oocyte	CL:0000655	96.88	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.85	gold quality
pigmented layer of retina	UBERON:0001782	96.82	gold quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	1280.59
E-MTAB-8221	yes	1192.53
E-MTAB-9067	yes	837.68
E-CURD-112	yes	471.61
E-HCAD-10	yes	49.90
E-HCAD-31	yes	20.72
E-MTAB-7316	yes	12.52
E-MTAB-10042	yes	11.18
E-CURD-114	yes	10.94
E-GEOD-83139	yes	6.78
E-MTAB-9801	yes	5.95
E-GEOD-93593	no	2510.67
E-MTAB-8894	no	1692.38
E-MTAB-9154	no	1218.85
E-MTAB-11121	no	1061.45

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

154 targeting NREP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872

Literature-anchored findings (GeneRIF, showing 16)

• role for P311 in inducing TGF-beta1-independent myofibroblast transformation (PMID:12417574)
• These results suggest a role for levels of P311 in regulating glioma motility and invasion through the reorganization of actin cytoskeleton at the cell periphery. (PMID:16229809)
• P311 expression is tightly regulated during the critical periods of alveolar formation, and that under pathologic conditions, its relative absence may contribute to failure of alveolar regeneration and lead to the development of human emphysema. (PMID:16484684)
• P311 may be involved in the pathogenesis of hypertrophic scar via induction of a myofibrobla (PMID:20404911)
• P311 and ITGB4BP expression was elevated in non-small cell lung cancer, possibly indicative of a new signaling pathway. (PMID:21029697)
• Protein HYI may closely bind with protein P311 by an alpha helix in hypertrophic scar fibroblasts. (PMID:22490543)
• P311 may promote the migration of ESCs both in micewith superficial partial-thickness burns and in an injured cell model in vitro, and it may play an important role in wound healing. (PMID:22967977)
• Novel RNA-binding protein P311 binds eIF3b to promote translation of TGF-beta1, TGF-beta2, TGF-beta3. (PMID:25336651)
• P311 plays a key role in renal fibrosis via TGFbeta1/Smad signaling, which could be a novel target for the management of renal fibrosis. (PMID:26616407)
• P311 is a novel TGFbeta1/Smad signaling-mediated regulator of transdifferentiation in epidermal stem cells during cutaneous wound healing. (PMID:27906099)
• P311 could accelerate skin wound reepithelialization by promoting the migration of Epidermal Stem Cell through RhoA and Rac1 activation. (PMID:27927130)
• These studies demonstrate that P311 is required for the production of normal cutaneous scars (PMID:27939132)
• P311 expression in the in the lungs of patients with idiopathic pulmonary fibrosis. (PMID:30230348)
• P311 Promotes IL-4 Receptor-Mediated M2 Polarization of Macrophages to Enhance Angiogenesis for Efficient Skin Wound Healing. (PMID:36309321)
• NREP contributes to development of NAFLD by regulating one-carbon metabolism in primary human hepatocytes. (PMID:37354909)
• H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP. (PMID:37742376)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nrep	ENSMUSG00000042834
rattus_norvegicus	Nrep	ENSRNOG00000068914

Protein

Protein identifiers

Neuronal regeneration-related protein — Q16612 (reviewed: Q16612)

Alternative names: Neuronal protein 3.1, Protein p311

All UniProt accessions (5): D6R982, Q16612, D6R9Y7, D6REJ5, D6RIC9

UniProt curated annotations — full annotation on UniProt →

Function. May have roles in neural function. Ectopic expression augments motility of gliomas. Also promotes axonal regeneration. May also have functions in cellular differentiation. Induces differentiation of fibroblast into myofibroblast and myofibroblast ameboid migration. Increases retinoic-acid regulation of lipid-droplet biogenesis. Down-regulates the expression of TGFB1 and TGFB2 but not of TGFB3. May play a role in the regulation of alveolar generation.

Subunit / interactions. Interacts with the latency-associated peptides (LAP) of TGFB1 and TGFB2; the interaction results in a decrease in TGFB autoinduction. Interacts with FLNA.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in lung (at protein level).

Post-translational modifications. Phosphorylated on Ser-59. Phosphorylation decreases stability and activity.

Induction. Down-regulated in emphysematous lung compared to normal lung.

Isoforms (2)

UniProt ID	Names	Canonical?
Q16612-1	1	yes
Q16612-2	2

RefSeq proteins (11): NP_001135946, NP_001135947, NP_001135948, NP_001135949, NP_001135950, NP_001135951, NP_001135952, NP_001135953, NP_001135954, NP_001135955, NP_004763* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024417	Neuronal_3.1	Family

Pfam: PF11092

UniProt features (8 total): mutagenesis site 2, chain 1, region of interest 1, compositionally biased region 1, modified residue 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16612-F1	67.60	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 59

Mutagenesis-validated functional residues (2):

Position	Phenotype
59	reduces protein degradation and induces glioma cell migration.
59	accelerates protein degradation and reduces glioma cell migration.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 351 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_DN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, AAGCAAT_MIR137, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_REGENERATION, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, GOBP_NEUROGENESIS, TGACCTY_ERR1_Q2, MEF2_02, GOBP_RESPONSE_TO_AXON_INJURY, LHX3_01, GGGTGGRR_PAX4_03

GO Biological Process (3): regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), axon regeneration (GO:0031103), regulation of neuron differentiation (GO:0045664)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transforming growth factor beta receptor signaling pathway	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
neuron projection regeneration	1
response to axon injury	1
axon development	1
neuron differentiation	1
regulation of cell differentiation	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

448 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NREP	MT2A	P02795	557
NREP	EIF3B	P55884	529
NREP	C1orf74	Q96LT6	495
NREP	H3BSS0	H3BSS0	468
NREP	RNF44	Q7L0R7	435
NREP	RNF38	Q9H0F5	400
NREP	PLXDC2	Q6UX71	400
NREP	TGFBR2	P37173	380
NREP	USP54	Q70EL1	373
NREP	C19orf67	A6NJJ6	371
NREP	ZSWIM8	A7E2V4	371
NREP	PCNX2	A6NKB5	369
NREP	PLSCR4	Q9NRQ2	352
NREP	CRLS1	Q9UJA2	352
NREP	EPB41L4A	Q9HCS5	349

IntAct

10 interactions, top by confidence:

A	B	Type	Score
EIF6	NREP	psi-mi:“MI:0915”(physical association)	0.630
NREP	EIF6	psi-mi:“MI:0915”(physical association)	0.630
NREP	EIF6	psi-mi:“MI:0403”(colocalization)	0.630
NREP	EEF1A1	psi-mi:“MI:0915”(physical association)	0.370
KMT2B	NREP	psi-mi:“MI:0915”(physical association)	0.370
ATM	NREP	psi-mi:“MI:0915”(physical association)	0.370
NREP	IGSF21	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (21): NREP (Two-hybrid), IGSF21 (Two-hybrid), MYH9 (Affinity Capture-MS), ACTB (Affinity Capture-MS), EIF3B (Affinity Capture-MS), FLNA (Affinity Capture-MS), GDI2 (Affinity Capture-MS), RAB7A (Affinity Capture-MS), EIF3G (Affinity Capture-MS), RPS13 (Affinity Capture-MS), RBMX (Affinity Capture-MS), NREP (Affinity Capture-Western), NREP (Reconstituted Complex), EIF3B (Reconstituted Complex), NREP (Affinity Capture-RNA)

ESM2 similar proteins: A0A1B0GUQ0, A0A1B0GV22, A4WGH3, A5WBB8, A8A6G6, B1IX34, B1X9T3, B5BIL7, B5QUQ3, B5RFY4, B7L848, B7LK47, B7M557, B7MGC6, B7N2F0, B7NF22, B7NR07, B8MYS5, C0Q2L2, C4ZYY2, O71190, O83770, P03167, P03168, P05443, P0A8C8, P0A8C9, P0C304, P0C305, P12173, P12478, P20464, P53231, P61468, P61472, Q16612, Q1R4N0, Q31UV8, Q329B3, Q3SSW2

Diamond homologs: Q07475, Q16612, Q4R541, Q5NVD3, Q80Z34, Q90667

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PRKCE	“down-regulates quantity by destabilization”	NREP	phosphorylation
PRKCZ	“down-regulates quantity by destabilization”	NREP	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	23
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2385 predictions. Top by Δscore:

Variant	Effect	Δscore
5:111731065:C:CT	acceptor_gain	1.0000
5:111731065:C:T	acceptor_gain	1.0000
5:111735423:ATCTT:A	donor_loss	1.0000
5:111735424:TCTTA:T	donor_loss	1.0000
5:111735425:CTTAC:C	donor_loss	1.0000
5:111735426:TTAC:T	donor_loss	1.0000
5:111735427:TACCT:T	donor_loss	1.0000
5:111735428:A:AG	donor_loss	1.0000
5:111735503:TAAAC:T	acceptor_gain	1.0000
5:111735507:CCTA:C	acceptor_loss	1.0000
5:111735508:C:CC	acceptor_gain	1.0000
5:111735509:T:G	acceptor_loss	1.0000
5:111926540:T:TA	donor_gain	1.0000
5:111731042:CTTCC:C	acceptor_gain	0.9900
5:111731044:TCC:T	acceptor_gain	0.9900
5:111731045:CCC:C	acceptor_gain	0.9900
5:111731067:C:CT	acceptor_gain	0.9900
5:111731069:C:CT	acceptor_gain	0.9900
5:111731071:C:CT	acceptor_gain	0.9900
5:111732871:A:C	donor_gain	0.9900
5:111735428:A:AC	donor_gain	0.9900
5:111735429:C:CC	donor_gain	0.9900
5:111914107:A:AC	donor_gain	0.9900
5:111914108:C:CC	donor_gain	0.9900
5:111926541:C:A	donor_gain	0.9900
5:111997320:ATAC:A	donor_loss	0.9900
5:111997321:TACCT:T	donor_loss	0.9900
5:111997323:C:CA	donor_loss	0.9900
5:111731043:TTCC:T	acceptor_gain	0.9800
5:111731045:CC:C	acceptor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000006715 (5:111753265 C>T), RS1000008558 (5:111790622 G>A,T), RS1000031900 (5:111871070 G>GTGTC), RS1000044006 (5:111772797 T>C), RS1000055706 (5:111904009 C>G,T), RS1000062076 (5:111914990 T>C), RS1000066471 (5:111865896 A>G), RS1000086468 (5:111762171 A>G), RS1000091534 (5:111917364 C>T), RS1000091950 (5:111753706 G>A), RS1000116097 (5:111812227 C>A,T), RS1000119823 (5:111827869 A>AG), RS1000132966 (5:111910339 T>G), RS1000135139 (5:111945901 C>T), RS1000140056 (5:111865438 G>A,T)

Disease associations

OMIM: gene MIM:607332 | disease phenotypes: MIM:192350

GenCC curated gene-disease

Mondo (1): VACTERL/vater association (MONDO:0008642)

Orphanet (1): VACTERL/VATER association (Orphanet:887)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST001762_458	Obesity-related traits	8.000000e-06
GCST002875_171	Diisocyanate-induced asthma	2.000000e-06
GCST003542_54	Night sleep phenotypes	4.000000e-06
GCST004144_8	Thyroid cancer	3.000000e-10
GCST004603_6	Platelet count	1.000000e-15
GCST004607_236	Plateletcrit	4.000000e-30
GCST004862_143	Itch intensity from mosquito bite adjusted by bite size	5.000000e-06
GCST004862_190	Itch intensity from mosquito bite adjusted by bite size	4.000000e-06
GCST004862_218	Itch intensity from mosquito bite adjusted by bite size	3.000000e-06
GCST004988_635	Breast cancer	4.000000e-09
GCST005993_5	Mean corpuscular hemoglobin	8.000000e-13
GCST005996_46	Red blood cell count	1.000000e-09
GCST006268_507	Reaction time	2.000000e-08
GCST009375_9	Mosaic loss of chromosome Y (Y chromosome dosage)	3.000000e-15
GCST010241_340	Apolipoprotein A1 levels	4.000000e-08
GCST012032_4	Platelet count	1.000000e-07
GCST90002383_211	Hematocrit	9.000000e-10
GCST90002383_212	Hematocrit	6.000000e-11
GCST90002390_137	Mean corpuscular hemoglobin	8.000000e-16
GCST90002392_636	Mean corpuscular volume	8.000000e-17
GCST90002395_456	Mean platelet volume	1.000000e-13
GCST90002396_309	Mean reticulocyte volume	1.000000e-14
GCST90002397_46	Mean spheric corpuscular volume	4.000000e-16
GCST90002400_647	Plateletcrit	8.000000e-65
GCST90002402_780	Platelet count	2.000000e-32
GCST90002403_409	Red blood cell count	2.000000e-12
GCST90002403_410	Red blood cell count	5.000000e-10
GCST90007007_5	Gut microbiota relative abundance (Sutterella)	9.000000e-06

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0004305	erythrocyte count
EFO:0008393	reaction time measurement
EFO:0007783	mosaic loss of chromosome Y measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004348	hematocrit
EFO:0010701	mean reticulocyte volume
EFO:0007874	gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

90 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases expression, affects cotreatment	4
bisphenol A	affects expression, affects cotreatment, decreases methylation, decreases expression	3
cobaltous chloride	decreases expression	3
nickel sulfate	decreases expression	3
Estradiol	affects expression, affects cotreatment, increases expression, decreases expression	3
Silicon Dioxide	decreases expression	3
Cyclosporine	decreases expression, decreases methylation	3
sulforaphane	decreases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
Zoledronic Acid	increases expression	2
Acetaminophen	decreases expression	2
Arsenic	increases abundance, decreases expression	2
Benzo(a)pyrene	increases methylation, decreases expression	2
Doxorubicin	affects response to substance, decreases expression	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Asbestos, Crocidolite	decreases expression	2
Cadmium Chloride	affects expression, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
sotorasib	affects cotreatment, decreases expression	1
chloroacetaldehyde	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
tobacco tar	decreases expression, decreases reaction	1
didecyldimethylammonium	decreases expression	1
periodate-oxidized adenosine	affects expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03799705	Not specified	COMPLETED	Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway